JP2005524696A - Ｎｒ２ｂレセプターアンタゴニストとしての３，４−ジヒドロキノリン−２（１ｈ）−オン化合物。 - Google Patents

Ｎｒ２ｂレセプターアンタゴニストとしての３，４−ジヒドロキノリン−２（１ｈ）−オン化合物。 Download PDF

Info

Publication number
JP2005524696A
JP2005524696A JP2003587800A JP2003587800A JP2005524696A JP 2005524696 A JP2005524696 A JP 2005524696A JP 2003587800 A JP2003587800 A JP 2003587800A JP 2003587800 A JP2003587800 A JP 2003587800A JP 2005524696 A JP2005524696 A JP 2005524696A
Authority
JP
Japan
Prior art keywords
disease
pharmaceutically acceptable
compound
pain
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003587800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005524696A5 (enExample
Inventor
河村光宏
Original Assignee
ファイザー株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー株式会社 filed Critical ファイザー株式会社
Publication of JP2005524696A publication Critical patent/JP2005524696A/ja
Publication of JP2005524696A5 publication Critical patent/JP2005524696A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003587800A 2002-04-26 2003-04-15 Ｎｒ２ｂレセプターアンタゴニストとしての３，４−ジヒドロキノリン−２（１ｈ）−オン化合物。 Withdrawn JP2005524696A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37593902P 2002-04-26 2002-04-26
PCT/IB2003/001556 WO2003091241A1 (en) 2002-04-26 2003-04-15 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists

Publications (2)

Publication Number Publication Date
JP2005524696A true JP2005524696A (ja) 2005-08-18
JP2005524696A5 JP2005524696A5 (enExample) 2006-06-08

Family

ID=29270728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003587800A Withdrawn JP2005524696A (ja) 2002-04-26 2003-04-15 Ｎｒ２ｂレセプターアンタゴニストとしての３，４−ジヒドロキノリン−２（１ｈ）−オン化合物。

Country Status (15)

Country Link
US (1) US6713490B2 (enExample)
EP (1) EP1499606B8 (enExample)
JP (1) JP2005524696A (enExample)
AR (1) AR039663A1 (enExample)
AT (1) ATE325117T1 (enExample)
AU (1) AU2003219398A1 (enExample)
BR (1) BR0309778A (enExample)
CA (1) CA2483636A1 (enExample)
DE (1) DE60305026T2 (enExample)
ES (1) ES2258716T3 (enExample)
MX (1) MXPA04010549A (enExample)
PA (1) PA8572601A1 (enExample)
TW (1) TW200406402A (enExample)
UY (1) UY27776A1 (enExample)
WO (1) WO2003091241A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010532761A (ja) * 2007-07-03 2010-10-14 ノノ インコーポレイテッド 不安に対する治療法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
MXPA06003748A (es) * 2003-10-08 2006-06-14 Pfizer Compuestos de lactama condensada.
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
US20070185168A1 (en) * 2004-04-07 2007-08-09 Takai Haruki S Piperidine derivatives
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
AU2009296457A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
WO2010113109A1 (en) * 2009-03-31 2010-10-07 Link Research & Grants Corporation Treatment of tinnitus and associated auditory dysfunctions
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
AU2013251079B2 (en) 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP0554247B1 (en) 1990-05-10 2000-04-26 Pfizer Inc. Neuroprotective indolone and related derivatives
PL173618B1 (pl) 1992-10-30 1998-04-30 Pfizer Związki 6-[2-(4-hydroksy-4-fenylopiperydyno)-1-hydroksypropylo]-3,4-dihydro-2(1H)-chinolonowe
PA8525601A1 (es) 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010532761A (ja) * 2007-07-03 2010-10-14 ノノ インコーポレイテッド 不安に対する治療法
US8536129B2 (en) 2007-07-03 2013-09-17 Nono Inc. Treatment for anxiety
JP2014129353A (ja) * 2007-07-03 2014-07-10 Nono Inc 不安に対する治療法

Also Published As

Publication number Publication date
ES2258716T3 (es) 2006-09-01
WO2003091241A1 (en) 2003-11-06
US6713490B2 (en) 2004-03-30
DE60305026T2 (de) 2006-10-12
US20030216430A1 (en) 2003-11-20
PA8572601A1 (es) 2004-12-16
BR0309778A (pt) 2005-03-08
TW200406402A (en) 2004-05-01
DE60305026D1 (de) 2006-06-08
AU2003219398A1 (en) 2003-11-10
AR039663A1 (es) 2005-03-02
UY27776A1 (es) 2003-11-28
EP1499606B1 (en) 2006-05-03
EP1499606A1 (en) 2005-01-26
MXPA04010549A (es) 2005-02-17
CA2483636A1 (en) 2003-11-06
ATE325117T1 (de) 2006-06-15
EP1499606B8 (en) 2006-08-30

Similar Documents

Publication Publication Date Title
JP7095106B2 (ja) オキサジアゾール一過性受容器電位チャネル阻害剤
MX2011012712A (es) Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
US20040204409A1 (en) Bicyclic compounds as NR2B receptor antagonists
JP6496730B2 (ja) 新規なオクタヒドロ−シクロブタ［１，２−ｃ；３，４−ｃ’］ジピロール−２−イル
US9802945B2 (en) Imidazopyridazine derivatives as modulators of the GABAA receptor activity
EP2491024B1 (en) Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
US6713490B2 (en) 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
JP6975515B2 (ja) Ｔｒｐａ１モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物
WO2016169504A1 (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
KR20150037950A (ko) 4-메틸-2,3,5,9,9ｂ-펜타아자-사이클로펜타[ａ]나프탈렌
US20120321559A1 (en) Hexahydro-pyrrolo-isoquinoline compounds
JPH10279578A (ja) 新規なアリールピペリジン化合物、その製造法、及びそれらを含む医薬組成物
JP2023554282A (ja) 置換ピペリジノ化合物及び関連する治療方法
TWI659741B (zh) 用於治療精神分裂症之氘化１－哌－３－苯基－二氫茚
CN118019533A (zh) 用于治疗中枢神经系统疾病的作为分拣蛋白调节剂的2-氨基-5,5-二甲基己酸衍生物
JP2019515021A (ja) フッ素含有トリアゾロピリジン系化合物、その製造方法、医薬組成物及び用途
US7671056B2 (en) Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor
JP2017206534A (ja) 新規化合物
KR20220118484A (ko) Oga 억제제 화합물
KR20220118483A (ko) Oga 억제제 화합물
JP2005525333A (ja) 置換縮合ピラゾールカルボン酸アリールアミド及び関連化合物
US10538523B2 (en) 4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain
JP2007508288A (ja) 縮合ラクタム化合物
JP2010536919A (ja) ノルエピネフリン、セロトニンまたはドーパミン再取り込み阻害剤として有用な３−アザビシクロ（４．１．０）ヘプタン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060412

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20061207